Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alice T Shaw

Showing results (81-90 of 204) with videos related to

Pageof 21
Sort By:
Clinical Lung Cancer|November 12, 2019
Computed Tomography Imaging Features and Distribution of Metastases in ROS1-rearranged Non-Small-cell Lung CancerSubba R Digumarthy, Dexter P Mendoza, Jessica J Lin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 15, 2016
Clinicopathologic Features of NSCLC Diagnosed During Pregnancy or the Peripartum Period in the Era of Molecular GenotypingIbiayi Dagogo-Jack, Justin F Gainor, Rebecca L Porter, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 23, 2016
Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non-Small Cell Lung Cancer: Results of a Phase I StudyPasi A Jänne, Alice T Shaw, D Ross Camidge, et al.
Lung Cancer (Amsterdam, Netherlands)|July 24, 2018
Clinical outcomes of patients with resected, early-stage ALK-positive lung cancerJamie E Chaft, Ibiayi Dagogo-Jack, Fernando C Santini, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 14, 2017
Circulating Tumor DNA Identifies EGFR Coamplification as a Mechanism of Resistance to Crizotinib in a Patient with Advanced MET-Amplified Lung AdenocarcinomaIbiayi Dagogo-Jack, David Fabrizio, Jochen Lennerz, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 22, 2019
Molecular Analysis of Plasma From Patients With ROS1-Positive NSCLCIbiayi Dagogo-Jack, Marguerite Rooney, Rebecca J Nagy, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 30, 2018
Safety of Combined PD-1 Pathway Inhibition and Intracranial Radiation Therapy in Non-Small Cell Lung CancerHarper G Hubbeling, Emily F Schapira, Nora K Horick, et al.
JCO Precision Oncology|May 18, 2022
Phase II Study of Lorlatinib in Patients With Anaplastic Lymphoma Kinase-Positive Lung Cancer and CNS-Specific RelapseIbiayi Dagogo-Jack, Geoffrey R Oxnard, Makenzi Evangelist, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 12, 2018
Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non-Small Cell Lung CancerJessica J Lin, Emily Chin, Beow Y Yeap, et al.
Cancer Research and Treatment|July 14, 2017
Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung CancerMakoto Nishio, Dong-Wan Kim, Yi-Long Wu, et al.
Pageof 21

Showing results (81-90 of 204) with videos related to

Sort By:
Pageof 21
Clinical Lung Cancer|November 12, 2019
Computed Tomography Imaging Features and Distribution of Metastases in ROS1-rearranged Non-Small-cell Lung CancerSubba R Digumarthy, Dexter P Mendoza, Jessica J Lin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 15, 2016
Clinicopathologic Features of NSCLC Diagnosed During Pregnancy or the Peripartum Period in the Era of Molecular GenotypingIbiayi Dagogo-Jack, Justin F Gainor, Rebecca L Porter, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 23, 2016
Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non-Small Cell Lung Cancer: Results of a Phase I StudyPasi A Jänne, Alice T Shaw, D Ross Camidge, et al.
Lung Cancer (Amsterdam, Netherlands)|July 24, 2018
Clinical outcomes of patients with resected, early-stage ALK-positive lung cancerJamie E Chaft, Ibiayi Dagogo-Jack, Fernando C Santini, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 14, 2017
Circulating Tumor DNA Identifies EGFR Coamplification as a Mechanism of Resistance to Crizotinib in a Patient with Advanced MET-Amplified Lung AdenocarcinomaIbiayi Dagogo-Jack, David Fabrizio, Jochen Lennerz, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 22, 2019
Molecular Analysis of Plasma From Patients With ROS1-Positive NSCLCIbiayi Dagogo-Jack, Marguerite Rooney, Rebecca J Nagy, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 30, 2018
Safety of Combined PD-1 Pathway Inhibition and Intracranial Radiation Therapy in Non-Small Cell Lung CancerHarper G Hubbeling, Emily F Schapira, Nora K Horick, et al.
JCO Precision Oncology|May 18, 2022
Phase II Study of Lorlatinib in Patients With Anaplastic Lymphoma Kinase-Positive Lung Cancer and CNS-Specific RelapseIbiayi Dagogo-Jack, Geoffrey R Oxnard, Makenzi Evangelist, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 12, 2018
Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non-Small Cell Lung CancerJessica J Lin, Emily Chin, Beow Y Yeap, et al.
Cancer Research and Treatment|July 14, 2017
Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung CancerMakoto Nishio, Dong-Wan Kim, Yi-Long Wu, et al.
Pageof 21